Drug class
Bone-seeking radiopharmaceutical ligand; samarium-153-labelled therapeutic radiopharmaceutical component
Mechanism of action
The ethylenediaminetetramethylene phosphonate (EDTMP) ligand chelates samarium-153 and localises to hydroxyapatite in areas of increased osteoblastic activity. The beta emissions from samarium-153 deliver targeted radiation to osteoblastic skeletal metastases.
General use cases
- Used as samarium-153 lexidronam pentasodium (Quadramet) for relief of bone pain in patients with multiple painful osteoblastic skeletal metastases that demonstrate uptake of technetium-labelled bisphosphonates on bone scintigraphy. The radionuclide-labelled product is the therapeutic radiopharmaceutical.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
